Emergent BioSolutions (NYSE:EBS) Posts Earnings Results, Misses Estimates By $1.50 EPS
Emergent BioSolutions (NYSE:EBS – Get Rating) released its earnings results on Tuesday. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($1.50), Briefing.com reports. The business had revenue of $165.10 million during the quarter, compared to analyst estimates of $142.85 million. Emergent BioSolutions had a negative net margin […]